



Contact Person	Shak Gohir, EEN Practice director		
Email	shak.gohir@cenamps.com		
Reference	Shak/08 GB47P80J04		
Release Date	1 st Oct 2008	Closing Date	15 th Oct 2008

Client profile and requirement summary	
Organisation Type	SME
Location	United Kingdom
Sectors	Security Applications - Diagnostics devices for detection of explosives, drugs, chemical, biological and radiological agents
Summary of requirement	<p>Our client is an SME based in the NorthEast, UK and has developed and patented a technology to produce positive detection lateral flow tests for small molecules such as drugs, toxins and explosives.</p> <p>Our client is looking for partners for FP7 Security SEC 2009 with the capabilities given below:</p> <ul style="list-style-type: none"> • First Responders/End Users

Description of technological expertise and capabilities required by our client
<p>The novel technology developed by our client provides a point of need, real time, <10min, highly sensitive test to trace amounts of <100ppt (ng/L). The result is visually easy to read as the presence of the target molecule is confirmed by the appearance of a coloured line. The test is robust and simple to use making it ideally suited to deployment by first responders in an emergency situation. Availability of this information will enable a safe, rapid and proactive response to the identified material. Although a reader is not essential for the positive lateral flow test, for recording and storing of results for evidence, a hand held digital reader can be used.</p> <p>The partners should be security organisations, Forensic Laboratories, and First Responder organisations requiring mobile technology for real-time detection of trace levels of 'small molecule' substances, e.g. explosives, toxins and drugs</p>

Research instrument
<p>European framework programme FP7 Security SEC 2009 Proposal submission deadline : 04/12/08</p>
<p>Our client is establishing a consortium to participate in a European Framework programme, funded by the European Commission under FP7 Security SEC 2009.</p>